Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1758MR)

This product GTTS-WQ1758MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1758MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12638MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ3946MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ4764MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ13264MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ3710MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ4754MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ389MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ12178MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW